Stock Screener App

Frei -

Installieren

8.36

3.34% 0.27

after-market

Handel nachbörslich: 8.31 -0.05 -0.60%

Atara Biotherapeutics Inc (ATRA)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt ATRA? Forum Prognose

Atara Biotherapeutics Inc Aktie (ATRA) Neueste Nachrichten

ATRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review

Atara Biotherapeutics (NASDAQ:ATRA) Rating Increased to Hold at Wall Street Zen - MarketBeat

Why (ATRA) Price Action Is Critical for Tactical Trading - Stock Traders Daily

Atara Biotherapeutics (ATRA): Point72 entities report 7.6% beneficial stake - Stock Titan

Atara Biotherapeutics Inc earnings missed by $0.10, revenue fell short of estimates - Investing.com Nigeria

Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress - BioSpace

Atara Biotherapeutics cuts costs 87%, extends cash runway to mid-2027 - scanx.trade

Is Atara Biotherapeutics Inc (ATRA) Positioned for Growth After - GuruFocus

Atara Biotherapeutics (NASDAQ:ATRA) Announces Quarterly Earnings Results - MarketBeat

Atara Biotherapeutics 2Q 2026: Revenue $0.63M, Net loss $(9.0)M — 10-Q Summary - TradingView

Atara Biotherapeutics: Q2 Earnings Snapshot - AOL.com

BRIEF-Atara Biotherapeutics Q2 EPS USD -0.32 - TradingView

Atara Biotherapeutics (ATRA) Earnings Date and Reports 2026 $ATRA - MarketBeat

Atara Biotherapeutics (NASDAQ:ATRA): What Could Today’s Update Reveal About Program Focus And Funding Discipline? - Kalkine Media

Atara Biotherapeutics Inc (ATRA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

ATRA DEADLINE REMINDER: Bronstein, Gewirtz & Grossman LLC Reminds - The National Law Review

Atara Biotherapeutics (NASDAQ:ATRA) Downgraded to "Sell" Rating by Wall Street Zen - MarketBeat

Atara Biotherapeutics, Inc. expected to post a loss of 31 cents a shareEarnings Preview - TradingView

ATRA Q2'26 Earnings: EPS estimate is (0.32) USD - TradingView

ATRA DEADLINEFINAL REMINDER: Bronstein, Gewirtz & Grossman LLC - The National Law Review

Understanding Momentum Shifts in (ATRA) - Stock Traders Daily

ATRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review

ATRA Q2'26 Earnings: revenue estimate is 550.00K USD - TradingView

Atara Biotherapeutics (ATRA) Projected to Release Earnings on Monday - MarketBeat

Enterprise value to revenue forward of Atara Biotherapeutics, Inc. – NASDAQ:ATRA - TradingView

Atara Biotherapeutics Inc (ATRA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

EcoR1 Capital LLC Sells 473,590 Shares of Atara Biotherapeutics, Inc. $ATRA - MarketBeat

Atara Biotherapeutics Inc (ATRA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Atara Biotherapeutics Inc (ATRA) Valuation: PE, PB & Fair Value Analysis - TradingKey

Atara Biotherapeutics Inc (ATRA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

Atara Biotherapeutics Inc (ATRA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

TradingKey - TradingKey

Form 13D/A Atara Biotherapeutics For: 24 July By Investing.com - Investing.com South Africa

Atara Biotherapeutics Inc (ATRA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Form 4 Atara Biotherapeutics Inc For: 24 July By Investing.com - Investing.com South Africa

Atara Biotherapeutics, Inc. Revenue Breakdown – NASDAQ:ATRA - TradingView

Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Shareholders to Connect - ACCESS Newswire

Redmile adjusts Atara Biotherapeutics (ATRA) ownership after warrant exercises - Stock Titan

ATRA|Atara Biotherapeutics Inc|Price:7.559|Chg%:-0.151 - TradingKey

Atara Biotherapeutics Inc (ATRA) Cash Flow - TradingKey

Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Shareholders to Inquire about Securities Investigation - ACCESS Newswire

Price to book forward of Atara Biotherapeutics, Inc. – NASDAQ:ATRA - TradingView

Avoiding Lag: Real-Time Signals in (ATRA) Movement - Stock Traders Daily

Atara Biotherapeutics (NASDAQ:ATRA) Share Price Passes Below 50-Day Moving AverageShould You Sell? - MarketBeat

Price to sales forward of Atara Biotherapeutics Inc – SWB:AT20 - TradingView

Price to book forward of Atara Biotherapeutics Inc – SWB:AT20 - TradingView

Enterprise value to revenue forward of Atara Biotherapeutics Inc – SWB:AT20 - TradingView

Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Connect - ACCESS Newswire

12 Health Care Stocks Moving In Monday's Pre-Market SessionAdvanced Biomed (NASDAQ:ADVB), Barinthus Bi - benzinga.com

Price to sales forward of Atara Biotherapeutics Inc – TRADEGATE:AT20 - TradingView

Enterprise value to EBITDA forward of Atara Biotherapeutics, Inc. – NASDAQ:ATRA - TradingView

2026-07-19 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Connect | NDAQ:ATRA | Press Release - Stockhouse

Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Stockholders to Inquire about Securities Investigation - ACCESS Newswire

Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biother - The National Law Review

Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewi - The National Law Review

Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeuti - The National Law Review

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review

2026-07-14 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Investors to Learn More About the Investigation | NDAQ:ATRA | Press Release - Stockhouse

Enterprise value to EBITDA forward of Atara Biotherapeutics Inc – MUN:AT20 - TradingView

Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

Enterprise value to EBIT forward of Atara Biotherapeutics Inc – MUN:AT20 - TradingView

MRNA

$64.46

1.80%

ROIV

$36.24

0.11%

RPRX

$59.45

1.45%

INSM

$128.32

3.70%

ALNY

$224.60

1.77%

ONC

$362.51

4.33%

In Yahoo öffnen | In Google öffnen | In Finviz öffnen | In MarketWatch öffnen | Öffnen Sie in EDGAR | Offen in Reuters